Blood Screening Market Size, Share and Growth Outlook, 2026

Blood Screening Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Blood Screening Market size is forecast to increase from $3.56 Billion in 2026 to $8.5 Billion in 2034 at a CAGR of 11.5% between 2026 and 2034.

The Blood Screening market report provides detailed analysis and outlook of Blood Screening segments including By Product & Service (Reagents and Kits, Instruments, Software and Services), By Technology (Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay, Rapid Tests, Western Blot Assay, Next-Generation Sequencing ), By Screening Target (Infectious Disease Panels, Blood Group Typing, Rare Antigen Genotyping), By End-User (Blood Banks, Hospitals, Clinical Laboratories, Plasma Fractionation Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Blood Screening Industry Overview

Advanced Screening Technologies Strengthening Blood Safety Programs

The blood screening industry remains a cornerstone of global transfusion medicine, ensuring the safety and quality of donated blood before clinical use. Blood screening technologies are essential for detecting infectious diseases, identifying potential health risks, and maintaining a secure blood supply for healthcare systems worldwide. Increasing emphasis on early disease detection, enhanced transfusion safety, and regulatory compliance is driving continued innovation across screening platforms. Advances in molecular diagnostics, high-throughput testing systems, and integrated laboratory technologies are enabling blood screening organizations to improve detection sensitivity, reduce diagnostic windows, and strengthen overall blood safety protocols.

Multi-Cancer Early Detection Tests Expanding Screening Applications

One of the most significant developments within the blood screening industry is the advancement of Multi-Cancer Early Detection (MCED) technologies. As of May 2026, clinical studies such as the PATHFINDER 2 trial demonstrated that MCED tests, when used alongside standard screening programs, can significantly improve cancer detection rates. These tests have shown particular value in identifying cancers that are not currently addressed by routine screening guidelines. The ability to detect multiple cancer types through a single blood sample is expanding the role of blood-based diagnostics beyond traditional infectious disease testing and supporting earlier intervention strategies in oncology care. Growing clinical validation is accelerating interest in MCED technologies across healthcare systems.

Multiplex NAT Platforms Enhancing Infectious Disease Detection

Nucleic Acid Testing (NAT) continues to represent the gold standard for blood screening applications. Recent technological advancements have focused on multiplex molecular platforms capable of simultaneously detecting multiple pathogens, including Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and syphilis from a single blood donation. These systems improve screening efficiency while reducing diagnostic window periods and increasing sensitivity for low-titer infections. The ability to identify multiple infectious agents through a single testing workflow strengthens blood safety programs and supports the industry's ongoing objective of maintaining the lowest possible risk of transfusion-transmitted infections.

Digital Integration Supporting Traceability and Regulatory Compliance

Modern blood screening laboratories are increasingly integrating high-throughput analyzers with laboratory information systems through advanced middleware platforms. This connectivity enables real-time traceability, automated data management, and streamlined regulatory reporting. Such integration has become a foundational requirement for centralized testing hubs seeking to comply with evolving health authority mandates and quality assurance standards. Enhanced digital connectivity improves operational visibility, facilitates audit readiness, and supports more efficient management of large testing volumes. As regulatory expectations continue to evolve, the integration of screening technologies with laboratory information infrastructure is becoming an essential component of modern blood safety and compliance programs.

Blood Screening Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Blood Screening market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Grifols, S.A., Abbott Laboratories, QuidelOrtho Corporation, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., PerkinElmer (Revvity). The Blood Screening market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Blood Screening industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Blood Screening Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Blood Screening companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Blood Screening markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Blood Screening Market Competitive Benchmarking and Company Analysis

Leading companies in Blood Screening industry include- F. Hoffmann-La Roche Ltd, Grifols, S.A., Abbott Laboratories, QuidelOrtho Corporation, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., PerkinElmer (Revvity). The Blood Screening market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Blood Screening Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Blood Screening market remains one of the strongest-performing segments in the country.
The US Blood Screening Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Blood Screening market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Blood Screening industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Blood Screening markets

Canada's strong Blood Screening sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Blood Screening market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Blood Screening Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Blood Screening market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Blood Screening population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Blood Screening industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Blood Screening market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Blood Screening sales through 2034

France Blood Screening companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Blood Screening Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Blood Screening distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Blood Screening Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Blood Screening market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Blood Screening industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Blood Screening industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Blood Screening Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Blood Screening market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Blood Screening market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Blood Screening Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Blood Screening Market Segmentation

By Product & Service
Reagents and Kits
Instruments
Software and Services
By Technology
Nucleic Acid Testing
Enzyme-Linked Immunosorbent Assay
Rapid Tests
Western Blot Assay
Next-Generation Sequencing
By Screening Target
Infectious Disease Panels
Blood Group Typing
Rare Antigen Genotyping
By End-User
Blood Banks
Hospitals
Clinical Laboratories
Plasma Fractionation Centers

Top Companies in Blood Screening Industry

F. Hoffmann-La Roche Ltd
Grifols, S.A.
Abbott Laboratories
QuidelOrtho Corporation
bioMérieux SA
Bio-Rad Laboratories, Inc.
Danaher Corporation
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
PerkinElmer (Revvity)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025